Key result
Transgenic mouse papillary muscles lacking specific PKC-dependent phosphorylation sites on cTnI showed only a 45% reduction in peak twitch force after phenylephrine treatment compared to a 62% reduction in nontransgenic muscles.
PKC-mediated phosphorylation of Ser43 and Ser45 on cardiac troponin I is a key regulator of force development in the myocardium, which may be relevant in heart failure.
Answers are grounded in this paper and cite their sources.
PKC-cTnI phosphorylation modulates force in murine myocardium; leaves open relevance to human heart failure mechanisms.
Protein kinase C (PKC)-mediated phosphorylation of cardiac myofilament (MF) proteins has been shown to depress the actomyosin interaction and may be important during heart failure. Biochemical studies indicate that phosphorylation of Ser(43) and Ser(45) of cardiac troponin I (cTnI) plays a substantial role in the PKC-mediated depression. We studied intact and detergent-extracted papillary muscles from nontransgenic (NTG) and transgenic (TG) mouse hearts that express a mutant cTnI (Ser43Ala, Ser45Ala) that lacks specific PKC-dependent phosphorylation sites. Treatment of NTG papillary muscles with phenylephrine (PE) resulted in a transient increase and a subsequent 62% reduction in peak twitch force. TG muscles showed no transient increase and only a 45% reduction in force. There was a similar difference in maximum tension between NTG and TG fiber bundles that had been treated with a phorbol ester and had received subsequent detergent extraction. Although levels of cTnI phosphorylation correlated with these differences, the TG fibers also demonstrated a decrease in phosphorylation of cardiac troponin T. The PKC-specific inhibitor chelerythrine inhibited these responses. Our data provide evidence that specific PKC-mediated phosphorylation of Ser(43) and Ser(45) of cTnI plays an important role in regulating force development in the intact myocardium.
No takes yet. Share an insight, caveat, or question.
Montgomery et al. (2002) studied Myocardial force development. Transgenic expression of mutant cTnI (Ser43Ala, Ser45Ala) vs. Nontransgenic (NTG) mouse hearts was evaluated on Reduction in peak twitch force after phenylephrine treatment. Transgenic mouse papillary muscles lacking specific PKC-dependent phosphorylation sites on cTnI showed only a 45% reduction in peak twitch force after phenylephrine treatment compared to a 62% reduction in nontransgenic muscles.
Synapse has enriched 10 related papers. Consider them for comparative context: